January 2026 in “Stem Cell Reviews and Reports” Hair graying may help prevent cancer by protecting stem cells.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
March 2026 in “Skin Appendage Disorders” Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.
Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.
Immune therapy for cancer can cause hair loss scars in some patients.
January 2026 in “Dermatologica Sinica” New and repurposed treatments are improving outcomes in dermatology.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
June 2023 in “Skin Health and Disease” New treatments are improving skin disease management and skin health.
March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
January 2026 in “Immunity & Inflammation” Autoimmune skin diseases result from genetic and environmental factors disrupting immune checkpoints.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
May 2025 in “Life Studies” Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.
New diabetes tech and therapies improve care for endocrine disorders.
October 2025 in “Transactions on Materials Biotechnology and Life Sciences” Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.
April 2019 in “Radiotherapy and oncology” HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
February 2024 in “Scientific reports” Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.
6 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
January 2023 in “Research Square (Research Square)” IGF2BP3 gene is up-regulated in keloid patients, suggesting potential targets for treatment.
77 citations
,
November 2018 in “Cell” Lung immune cells can be trained to better fight infections after a virus.
32 citations
,
August 2019 in “Nature Communications” Chemotherapy causes permanent hair follicle damage by triggering stem cell loss.
Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
2 citations
,
November 2024 in “JAAD Case Reports” Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.
3 citations
,
October 2024 in “Cancers” Skin side effects from melanoma immunotherapy are common and may indicate better survival.